ClinicalTrials.gg
CompletedNCT00762463Updated Feb 2, 2021Results posted

Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis

A Phase 3 interventional study of Celecoxib and Diclofenac SR in Ankylosing Spondylitis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
21st of 62
240 · median 150
Started
2009
the only one that year
Phase 3
18 of 76
4 open now
Registered
3rd of 76
by date

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 21st largest by enrollment of the 62 interventional ones that give a count, is the only one that started in 2009, is one of 18 in phase 3, and was the 3rd registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the 1984 Modified New York Criteria for Classification of Ankylosing Spondylitis
  • With axial involvement
  • Without peripheral joint involvement (synovitis) at the time of study entry, (excluding involvement of the hips, knees and shoulders)
  • Need for daily treatment with NSAIDs during the previous 30 days before study entry

Exclusion criteria

Exclusion Criteria:

  • Known inflammatory enteropathy (eg, ulcerative colitis, Crohn's disease, etc)
  • Presence of extra-articular manifestations (eg, uveitis, endocarditis, etc.)
  • Known vertebral compression
  • Need for a corset during the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Celecoxib 200 mg QD

    Drug: Celecoxib

  • Active comparator
    Diclofenac SR 75 mg QD

    Drug: Diclofenac SR

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6

    100-millimeter (mm) Visual Analog Scale (VAS) score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of less than (\<) 0 indicated improvement.

    Time frame: Baseline, Week 6

  2. Participant's Assessment of Global Pain Intensity at Baseline

    100-mm VAS scores specified participant's assessment of global pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain.

    Time frame: Baseline

Secondary outcomes

  1. Change From Baseline in Participant's Assessment of Global Pain Intensity at Weeks 2 and 4

    100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of \<0 indicated improvement.

    Time frame: Baseline, Weeks 2, 4

  2. Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 12

    100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain. Change from baseline of \<0 indicated improvement.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Participant's Global Assessment of Disease Activity at Weeks 2, 4, and 6

    5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 6

  4. Change From Baseline in Participant's Global Assessment of Disease Activity at Week 12

    5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, and 6

    5-point Likert scale scores specified physician's subjective assessment on how overall ankylosing spondylitis appeared at the time of participant's visit and participant's disease signs. 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 6

  6. Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12

    5-point Likert scale scores specified physician's subjective assessment on how the overall ankylosing spondylitis appeared at the time of the participant's visit and participant's disease signs. 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, and 6

    Bath Ankylosing Spondylitis Functional Index (BASFI) was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 6

  8. Change From Baseline in BASFI at Week 12

    BASFI was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Lower scores indicated better functional health. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, and 6

    Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was comprised of 6 specific questions, each answered on a 10-mm VAS scale. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 6

  10. Change From Baseline in BASDAI at Week 12

    BASDAI is comprised of 6 specific questions, each answered on a 10-mm VAS. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Lower scores indicated better health. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 12

  11. Percentages of Participants Responding to Assessment in Ankylosing Spondylitis (ASAS)-20

    Percentages of participants who demonstrated an improvement of greater than or equal to (≥) 20% from baseline and an absolute improvement of ≥10 mm from baseline on a 100-mm VAS in ≥3 of the 4 domains proposed by the Ankylosing Spondylitis Assessment Working Group (ASAS-20).

    Time frame: Weeks 2, 4, 6, 12

  12. Change From Baseline in Nocturnal Pain at Weeks 2, 4, and 6

    100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 6

  13. Change From Baseline in Nocturnal Pain at Week 12

    100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Lower scores indicated less pain. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 12

  14. Change From Baseline in Fingertips to Floor Distance at Weeks 2, 4, and 6

    Fingertips to floor distance measured in centimeter (cm) from the tip of the fingers to the floor with participants standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 6

  15. Change From Baseline in Fingertips to Floor Distance at Week 12

    Fingertips to floor distance measured in cm from the tip of the fingers to the floor with participant standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Lower scores indicated better health. Change from baseline \<0 represented improvement.

    Time frame: Baseline, Week 12

  16. Change From Baseline in Chest Expansion at Weeks 2, 4, and 6

    Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Change from baseline greater than (\>) 0 represented improvement.

    Time frame: Baseline, Weeks 2, 4, 6

  17. Change From Baseline in Chest Expansion at Week 12

    Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (\>) 0 represented improvement.

    Time frame: Baseline, Week 12

  18. Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6

    Erythrocyte Sedimentation Rate (ESR) was a laboratory test that providee a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 6

  19. Change From Baseline in ESR at Week 12

    ESR was a laboratory test that provided a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube. Lower values indicated better health. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 12

  20. Change From Baseline in C-Reactive Protein (CRP) at Week 6

    C-Reactive Protein (CRP) was a marker of inflammation, measured in milligram per liter (mg/L). Change from baseline \<0 indicated improvement.

    Time frame: Baseline, 6 Weeks

  21. Change From Baseline in CRP at Week 12

    CRP was a marker of inflammation. Lower values indicated better health. Change from baseline \<0 indicated improvement.

    Time frame: Baseline, Week 12

  22. Percentage of Participants With Concomitant Use of Paracetamol

    Percentage of participants who concomitantly took at least 1 paracetamol tablet as rescue medication at Week 6

    Time frame: Week 6

  23. Percentage of Days With Concomitant Administration of Paracetamol

    Calculated as days on rescue medication divided by days of exposure in the study at the end of Week 6.

    Time frame: Week 6

  24. Paracetamol Tablets Taken Per Day by Participant

    Calculated as the total number of paracetamol tablets taken divided by days of exposure in the study.

    Time frame: Week 6

07

Results

Posted Aug 23, 2011
Limitations and caveats
The protocol does not specify time points for secondary endpoints; these are described in the statistical analysis plan.

Participant flow

Double-blind Phase (Baseline to Week 6)
Participant flow — Double-blind Phase (Baseline to Week 6)
MilestoneCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Started12012000
Completed11311000
Not completed71000
Withdrew: Insufficient clinical response2200
Withdrew: No longer willing to participate3400
Withdrew: Adverse event2400
Enrollment in Extension Phase (Week 6)
Participant flow — Enrollment in Extension Phase (Week 6)
MilestoneCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Started11311000
Completed10910900
Not completed4100
Withdrew: Did not sign 2nd informed consent form4100
Extension Phase (Week 6 to Week 12)
Participant flow — Extension Phase (Week 6 to Week 12)
MilestoneCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Started55555454
Completed52545052
Not completed3142
Withdrew: Lost to follow-up1010
Withdrew: Insufficient clinical response1101
Withdrew: No longer willing to participate1030
Withdrew: Other0001

Outcome measures

PrimaryChange From Baseline in Participant's Assessment of Global Pain Intensity at Week 6

100-millimeter (mm) Visual Analog Scale (VAS) score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of less than (\<) 0 indicated improvement.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · mm
Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6
mmCelecoxib 200 mgDiclofenac SR 75 mg
Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6-23.8 ± 1.98-27.1 ± 2.02
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.0085 · Ls mean difference: 3.3 · 95% CI -2.2 to 8.8Analysis of covariance (ANCOVA); factors: treatment group and study center; covariate: baseline Patient's Assessment of Global Pain Intensity score.
PrimaryParticipant's Assessment of Global Pain Intensity at Baseline

100-mm VAS scores specified participant's assessment of global pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain.

Time frame:
Baseline
Reported as:
Mean · mm
Participant's Assessment of Global Pain Intensity at Baseline
mmCelecoxib 200 mgDiclofenac SR 75 mg
Participant's Assessment of Global Pain Intensity at Baseline62.9 ± 12.6863.6 ± 13.38
SecondaryChange From Baseline in Participant's Assessment of Global Pain Intensity at Weeks 2 and 4

100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of \<0 indicated improvement.

Time frame:
Baseline, Weeks 2, 4
Reported as:
Least squares mean · mm
Change From Baseline in Participant's Assessment of Global Pain Intensity at Weeks 2 and 4
mmCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=116, 115)-18.6 ± 1.78-17.9 ± 1.79
Week 4 (n=117, 115)-20.7 ± 1.86-23.3 ± 1.89
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.7849 · Ls mean difference: -0.7 · 95% CI -5.6 to 4.2Change from baseline analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.3223 · Ls mean difference: 2.6 · 95% CI -2.6 to 7.8Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in Participant's Assessment of Global Pain Intensity at Week 12

100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain. Change from baseline of \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mm
Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 12
mmCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)63.4 ± 13.5861.1 ± 13.0863.4 ± 12.0565.6 ± 13.26
Change from Baseline at Week 12 (n=52, 54, 46, 51)-28.4 ± 21.39-30.9 ± 24.24-20.8 ± 21.86-28.1 ± 25.96
SecondaryChange From Baseline in Participant's Global Assessment of Disease Activity at Weeks 2, 4, and 6

5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Participant's Global Assessment of Disease Activity at Weeks 2, 4, and 6
units on a scaleCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=116, 115)-0.4 ± 0.06-0.4 ± 0.06
Week 4 (n=117, 115)-0.3 ± 0.06-0.4 ± 0.06
Week 6 (n=117, 115)-0.3 ± 0.06-0.4 ± 0.06
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.8938 · Ls mean difference: 0.0 · 95% CI -0.15 to 0.17Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.0426 · Ls mean difference: 0.2 · 95% CI 0.01 to 0.31Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.1502 · Ls mean difference: 0.1 · 95% CI -0.05 to 0.29Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in Participant's Global Assessment of Disease Activity at Week 12

5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Participant's Global Assessment of Disease Activity at Week 12
units on a scaleCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)3.1 ± 0.833.0 ± 0.643.2 ± 0.663.2 ± 0.70
Change from Baseline at Week 12 (n=52, 54, 46, 51)-0.6 ± 0.99-0.6 ± 0.78-0.4 ± 0.71-0.6 ± 0.96
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, and 6

5-point Likert scale scores specified physician's subjective assessment on how overall ankylosing spondylitis appeared at the time of participant's visit and participant's disease signs. 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, and 6
units on a scaleCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=116, 115)-0.4 ± 0.05-0.4 ± 0.05
Week 4 (n=117, 115)-0.4 ± 0.05-0.5 ± 0.05
Week 6 (n=117, 115)-0.5 ± 0.06-0.5 ± 0.06
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.5945 · Ls mean difference: 0.0 · 95% CI -0.2 to 0.1Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.3427 · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.6522 · Ls mean difference: 0.0 · 95% CI -0.1 to 0.2Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity at Week 12

5-point Likert scale scores specified physician's subjective assessment on how the overall ankylosing spondylitis appeared at the time of the participant's visit and participant's disease signs. 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12
units on a scaleCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)3.2 ± 0.573.0 ± 0.453.2 ± 0.433.3 ± 0.50
Change from Baseline at Week 12 (n=52, 54, 46, 51)-0.7 ± 0.60-0.5 ± 0.64-0.5 ± 0.51-0.7 ± 0.75
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, and 6

Bath Ankylosing Spondylitis Functional Index (BASFI) was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 6
Reported as:
Least squares mean · mm
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, and 6
mmCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=116, 115)-0.3 ± 0.13-0.3 ± 0.13
Week 4 (n=117, 115)-0.4 ± 0.14-0.6 ± 0.14
Week 6 (n=117, 115)-0.5 ± 0.15-0.8 ± 0.15
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.9358 · Ls mean difference: 0.0 · 95% CI -0.3 to 0.4Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.5916 · Ls mean difference: 0.1 · 95% CI -0.3 to 0.5Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.1790 · Ls mean difference: 0.3 · 95% CI -0.1 to 0.7Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in BASFI at Week 12

BASFI was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Lower scores indicated better functional health. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mm
Change From Baseline in BASFI at Week 12
mmCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)3.4 ± 1.983.5 ± 2.133.5 ± 1.833.5 ± 2.25
Change from Baseline at Week 12 (n=52, 54, 46, 51)-0.9 ± 1.78-1.0 ± 1.64-0.6 ± 1.97-1.0 ± 2.30
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, and 6

Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was comprised of 6 specific questions, each answered on a 10-mm VAS scale. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 6
Reported as:
Least squares mean · mm
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, and 6
mmCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=116, 115)-0.8 ± 0.14-0.9 ± 0.14
Week 4 (n=117, 115)-0.9 ± 0.15-1.1 ± 0.15
Week 6 (n=117, 115)-1.1 ± 0.16-1.4 ± 0.16
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.6335 · Ls mean difference: 0.1 · 95% CI -0.3 to 0.5Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.2729 · Ls mean difference: 0.2 · 95% CI -0.2 to 0.6Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.1559 · Ls mean difference: 0.3 · 95% CI -0.1 to 0.8Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in BASDAI at Week 12

BASDAI is comprised of 6 specific questions, each answered on a 10-mm VAS. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Lower scores indicated better health. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mm
Change From Baseline in BASDAI at Week 12
mmCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)4.71 ± 1.794.9 ± 1.804.7 ± 1.484.9 ± 1.88
Change from Baseline at Week 12 (n=52, 54, 46, 51)-1.7 ± 1.86-2.1 ± 1.94-0.6 ± 1.87-1.4 ± 2.14
SecondaryPercentages of Participants Responding to Assessment in Ankylosing Spondylitis (ASAS)-20

Percentages of participants who demonstrated an improvement of greater than or equal to (≥) 20% from baseline and an absolute improvement of ≥10 mm from baseline on a 100-mm VAS in ≥3 of the 4 domains proposed by the Ankylosing Spondylitis Assessment Working Group (ASAS-20).

Time frame:
Weeks 2, 4, 6, 12
Reported as:
Number · percentage of participants
Percentages of Participants Responding to Assessment in Ankylosing Spondylitis (ASAS)-20
percentage of participantsCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac 75 mg, Then Celecoxib 400 mg
Week 2 (n=115, 114)23.525.400
Week 4 (n=116, 114)26.731.600
Week 6 (n=54, 54, 54, 54)40.742.622.229.6
Week 12 (n=51, 53, 46, 51)49.047.232.637.3
SecondaryChange From Baseline in Nocturnal Pain at Weeks 2, 4, and 6

100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 6
Reported as:
Least squares mean · mm
Change From Baseline in Nocturnal Pain at Weeks 2, 4, and 6
mmCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=116, 115)-12.0 ± 1.90-16.3 ± 1.91
Week 4 (n=117, 115)-14.5 ± 1.94-17.1 ± 1.96
Week 6 (n=117, 115)-15.4 ± 1.95-19.4 ± 1.98
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.1111 · Ls mean difference: 4.3 · 95% CI -1.0 to 9.5Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.3574 · Ls mean difference: 2.5 · 95% CI -2.9 to 7.9Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.1464 · Ls mean difference: 4.0 · 95% CI -1.4 to 9.5Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in Nocturnal Pain at Week 12

100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Lower scores indicated less pain. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mm
Change From Baseline in Nocturnal Pain at Week 12
mmCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)52.2 ± 20.4555.1 ± 19.2454.5 ± 20.1461.5 ± 19.17
Change from Baseline at Week 12 (n=52, 54, 46, 51)-19.4 ± 22.54-27.5 ± 25.62-12.5 ± 20.31-22.6 ± 30.36
SecondaryChange From Baseline in Fingertips to Floor Distance at Weeks 2, 4, and 6

Fingertips to floor distance measured in centimeter (cm) from the tip of the fingers to the floor with participants standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 6
Reported as:
Least squares mean · cm
Change From Baseline in Fingertips to Floor Distance at Weeks 2, 4, and 6
cmCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=117, 115)-1.6 ± 0.62-1.6 ± 0.62
Week 4 (n=118, 115)-1.9 ± 0.69-2.2 ± 0.71
Week 6 (n=118, 115)-2.8 ± 0.67-3.1 ± 0.69
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.9641 · Ls mean difference: 0.0 · 95% CI -1.7 to 1.8Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.7749 · Ls mean difference: 0.3 · 95% CI -1.6 to 2.2Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.7529 · Ls mean difference: 0.3 · 95% CI -1.6 to 2.2Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in Fingertips to Floor Distance at Week 12

Fingertips to floor distance measured in cm from the tip of the fingers to the floor with participant standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Lower scores indicated better health. Change from baseline \<0 represented improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · cm
Change From Baseline in Fingertips to Floor Distance at Week 12
cmCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)14.8 ± 12.8917.6 ± 15.2322.9 ± 19.4914.6 ± 14.48
Change from Baseline at Week 12 (n=52, 54, 46, 51)-3.0 ± 9.38-3.7 ± 6.82-3.1 ± 8.18-1.3 ± 7.75
SecondaryChange From Baseline in Chest Expansion at Weeks 2, 4, and 6

Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Change from baseline greater than (\>) 0 represented improvement.

Time frame:
Baseline, Weeks 2, 4, 6
Reported as:
Least squares mean · cm
Change From Baseline in Chest Expansion at Weeks 2, 4, and 6
cmCelecoxib 200 mgDiclofenac SR 75 mg
Week 2 (n=117, 115)0.2 ± 0.080.3 ± 0.08
Week 4 (n=118, 115)0.6 ± 0.090.4 ± 0.09
Week 6 (n=118, 115)0.7 ± 0.100.6 ± 0.10
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.8780 · Ls mean difference: 0.0 · 95% CI -0.2 to 0.2Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.2202 · Ls mean difference: 0.2 · 95% CI -0.1 to 0.4Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.5340 · Ls mean difference: 0.1 · 95% CI -0.2 to 0.4Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in Chest Expansion at Week 12

Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (\>) 0 represented improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · cm
Change From Baseline in Chest Expansion at Week 12
cmCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=55, 55, 54, 54)3.9 ± 1.933.8 ± 1.633.6 ± 1.823.8 ± 1.62
Change from Baseline at Week 12 (n=52, 54, 46, 51)0.8 ± 1.260.8 ± 1.390.8 ± 1.290.8 ± 1.02
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6

Erythrocyte Sedimentation Rate (ESR) was a laboratory test that providee a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · mm/h
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6
mm/hCelecoxib 200 mgDiclofenac SR 75 mg
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6-2.5 ± 1.30-1.8 ± 1.30
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.7003 · Ls mean difference: -0.7 · 95% CI -4.3 to 2.9Change from baseline analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in ESR at Week 12

ESR was a laboratory test that provided a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube. Lower values indicated better health. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mm/h
Change From Baseline in ESR at Week 12
mm/hCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=54, 54, 52, 54)20.9 ± 14.6020.8 ± 18.9822.8 ± 21.9923.6 ± 19.64
Change from Baseline at Week 12 (n=45, 44, 41, 43)-3.5 ± 13.96-1.3 ± 11.14-6.3 ± 13.46-0.7 ± 19.47
SecondaryChange From Baseline in C-Reactive Protein (CRP) at Week 6

C-Reactive Protein (CRP) was a marker of inflammation, measured in milligram per liter (mg/L). Change from baseline \<0 indicated improvement.

Time frame:
Baseline, 6 Weeks
Reported as:
Least squares mean · mg/L
Change From Baseline in C-Reactive Protein (CRP) at Week 6
mg/LCelecoxib 200 mgDiclofenac SR 75 mg
Change From Baseline in C-Reactive Protein (CRP) at Week 6-4.16 ± 1.587-2.72 ± 1.600
Statistical analysis
  • Celecoxib 200 mg vs Diclofenac SR 75 mg · ANCOVA · p = 0.5183 · Ls mean difference: -1.44 · 95% CI -5.82 to 2.94Change from baseline analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.
SecondaryChange From Baseline in CRP at Week 12

CRP was a marker of inflammation. Lower values indicated better health. Change from baseline \<0 indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mg/L
Change From Baseline in CRP at Week 12
mg/LCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Baseline (n=53, 55, 53, 54)18.53 ± 28.74915.84 ± 20.46418.80 ± 25.77421.01 ± 21.360
Change from Baseline at Week 12 (n=47, 49, 42, 47)-4.58 ± 9.682-2.99 ± 13.242-4.77 ± 24.656-2.13 ± 20.879
SecondaryPercentage of Participants With Concomitant Use of Paracetamol

Percentage of participants who concomitantly took at least 1 paracetamol tablet as rescue medication at Week 6

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Concomitant Use of Paracetamol
percentage of participantsCelecoxib 200 mgDiclofenac SR 75 mg
Percentage of Participants With Concomitant Use of Paracetamol2.50.0
SecondaryPercentage of Days With Concomitant Administration of Paracetamol

Calculated as days on rescue medication divided by days of exposure in the study at the end of Week 6.

Time frame:
Week 6
Reported as:
Mean · percentage of days
Percentage of Days With Concomitant Administration of Paracetamol
percentage of daysCelecoxib 200 mgDiclofenac SR 75 mg
Percentage of Days With Concomitant Administration of Paracetamol0.1 ± 0.080.0 ± 0.00
SecondaryParacetamol Tablets Taken Per Day by Participant

Calculated as the total number of paracetamol tablets taken divided by days of exposure in the study.

Time frame:
Week 6
Reported as:
Mean · tablets per day
Paracetamol Tablets Taken Per Day by Participant
tablets per dayCelecoxib 200 mgDiclofenac SR 75 mg
Paracetamol Tablets Taken Per Day by Participant0.2 ± 0.160.0 ± 0.00

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib 200 mg—0/120 (0%)11/120 (9.2%)
Diclofenac SR 75 mg—0/120 (0%)9/120 (7.5%)
Celecoxib 200 mg, Then Celecoxib 200 mg—0/54 (0%)0/54 (0%)
Diclofenac SR 75 mg, Then Diclofenac SR 75 mg—0/55 (0%)6/55 (10.9%)
Celecoxib 200 mg, Then Celecoxib 400 mg—0/53 (0%)5/53 (9.4%)
Diclofenac SR 75 mg, Then Celecoxib 400 mg—0/54 (0%)6/54 (11.1%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventCelecoxib 200 mgDiclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 200 mgDiclofenac SR 75 mg, Then Diclofenac SR 75 mgCelecoxib 200 mg, Then Celecoxib 400 mgDiclofenac SR 75 mg, Then Celecoxib 400 mg
Upper respiratory tract infectionInfections and infestations4/1201/1200/540/550/532/54
Alanine aminotransferase increasedInvestigations0/1200/1200/542/551/532/54
BronchitisInfections and infestations0/1200/1200/540/551/530/54
Transaminases increasedInvestigations0/1200/1200/541/551/530/54
Weight decreasedInvestigations0/1200/1200/540/551/530/54
White blood cell count decreasedInvestigations0/1200/1200/540/551/530/54
Abdominal painGastrointestinal disorders0/1200/1200/540/550/531/54
Hepatic function abnormalHepatobiliary disorders0/1202/1200/541/550/531/54
AnaemiaBlood and lymphatic system disorders0/1200/1200/541/550/530/54
Aspartate aminotransferase increasedInvestigations0/1200/1200/541/550/530/54

Baseline characteristics

Age, Customized
Age, Customized(participants)Celecoxib 200 mgDiclofenac SR 75 mgTotal
18 - 44 years109109218
45 - 64 years111122
Sex: Female, Male
Sex: Female, Male(Participants)Celecoxib 200 mgDiclofenac SR 75 mgTotal
Female151934
Male105101206
08

Study locations

5 sites
  • Pfizer Investigational Site
    Guangzhou, Guangdong 510630, China
  • Pfizer Investigational Site
    Xi'an, Shanxi 710032, China
  • Pfizer Investigational Site
    Chengdu, Sichuan 610041, China
  • Pfizer Investigational Site
    Beijing, 100020, China
  • Pfizer Investigational Site
    Beijing, 100853, China
09

References and documents

Publications

  • Huang F, Gu J, Liu Y, Zhu P, Zheng Y, Fu J, Pan S, Le S. Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp. 2014 Dec 5;76:126-33. doi: 10.1016/j.curtheres.2014.08.002. eCollection 2014 Dec. PubMed 25516774 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jun 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2008
First posted
Sep 30, 2008
Start
Jul 2009
Primary completionActual
Jun 2010
CompletionActual
Aug 2010
Results first posted
Aug 23, 2011
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00762463
Responsible party
Sponsor
First posted
Sep 30, 2008
Start date
Jul 2009
Primary completion
Jun 2010
Completion
Aug 2010
Results posted
Aug 23, 2011
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion